- Correction
- Open Access
- Published:
Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Biomarker Research volume 7, Article number: 21 (2019)
The Original Article was published on 11 September 2019
Correction to: Biomark Res (2019) 7:19
https://doi.org/10.1186/s40364-019-0170-2
The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for ‘mitoxantrone, etoposide, cyclophosphamide’.
It should instead be stated that MEC stands for ‘mitoxantrone, etoposide, cytarabine’.
Reference
- 1.
Zhao J, Song Y, Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomarker Research. 2019;7:19. https://doi.org/10.1186/s40364-019-0170-2.
Author information
Affiliations
Corresponding authors
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Zhao, J., Song, Y. & Liu, D. Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomark Res 7, 21 (2019). https://doi.org/10.1186/s40364-019-0172-0
Published: